MEDICORTEX-FINLAND
Medicortex Finland Oy announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent for a product candidate of New Chemical Entity (NCE) for prevention of long term effects of concussion and Traumatic Brain Injury (TBI). The compounds are targeting several biochemical processes of brain deterioration, thus being capable of halting the expansion of destructive secondary injuries typically following the original injury. Such a drug will have a large demand since there is no proper medical treatment available for TBI currently.
First filed and recently issued in Finland, the patent with the name of “Multivalent compounds for use in the treatment and prevention of brain damage” verifies Medicortex’s unique approach to preventing long term effects of head injury and opens up the possibilities for international collaborations. Equivalent applications are still pending in the European Patent Office (EPO) and Israel.
Dr. Adrian Harel, CEO of Medicortex Finland stated "We are pleased to announce the approval of this patent as it provides a basis for developing our first product for TBI treatment as part of our international expansion plan. Importantly, this patent reinforces the uniqueness of our drug development technology" concluded Dr. Harel.
The patent approval within such a high need pharma industry is of great importance and a big break-through for Medicortex Finland.
About Medicortex Finland Oy
Medicortex Finland Oy (http://www.medicortex.fi ) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is to develop biomarker based diagnostics to evaluate the presence and severity of TBI. Once the company completes this diagnostic kit development its next goal will be to develop an innovative drug to halt the progression of brain injury.
Forward-Looking Statements
This press release contains statements that are "forward-looking statements" that are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Keywords : head injury, trauma, brain injury, TBI, concussion, diagnostics, NCE, drug development, patent
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531005635/en/
Contact:
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358
(0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VA-DATAXSTREAM23.4.2024 15:08:30 CEST | Press release
DataXstream Expands into Nordic Region with Successful Go Live for Martin & Servera
NY-AUTEL-ENERGY23.4.2024 15:01:29 CEST | Press release
Autel Energy’s Global ESG Launch Is A Success: Around 5,000 Trees Planted In EVergreen's Inaugural Tree Planting Initiative
TX-OURO23.4.2024 14:01:58 CEST | Press release
Ouro Partners with Bnext as Strategic Issuer for European Expansion Plans
DC-EIG23.4.2024 14:01:58 CEST | Press release
EIG’s MidOcean Energy Completes Acquisition of 20 Percent Stake in Peru LNG
NY-MOODY'S/METLIFE23.4.2024 14:01:27 CEST | Press release
Moody’s Teams Up with the New York Giants and New York Jets as the New Cornerstone Partner of MetLife Stadium
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom